73167-03-0

Basic information

• Product Name: EPA
• Synonyms: 5C,8C,11C,14C,17C-EICOSAPENTAENOIC ACID;5,8,11,14,17-EICOSAPENTAENOIC ACID;5Z,8Z,11Z,14Z,17Z-EICOSAPENTAENOIC ACID;ALL CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID;ALL CIS 5-8-11-14-17 EPA;ALL CIS-5,8,11,14,17-ICOSAPENTAENOIC ACID;C20:5 (ALL CIS-5,8,11,14,17) ACID;C20:5 OMEGA-3
• CAS NO: 73167-03-0
• Molecular Formula: C20H29O2.Na
• Molecular Weight: 324.44
• Product Categories: Lipoxygenase (5-)Unsaturated fatty acids and derivatives;LipoxygenaseEnzyme Inhibitors by Enzyme;Omega 3 fatty acids and derivativesBiochemicals Found in Plants;Arachidonic Acid Cascade;Enzyme Inhibitors;L to;Lipids;Polyunsaturated
• Mol File: 73167-03-0.mol
• Article Data: 0

Chemical Properties

• Melting Point: −54-−53 °C(lit.)
• Boiling Point: 439.3°C at 760 mmHg
• Flash Point: 336°C
• Appearance: white/waxy solid
• Density: 0.943 g/mL at 25 °C(lit.)
• Vapor Pressure: 6.04E-09mmHg at 25°C
• Refractive Index: n20/D 1.4977(lit.)
• Storage Temp.: −20°C
• CAS DataBase Reference: EPA(CAS DataBase Reference)
• NIST Chemistry Reference: EPA(73167-03-0)
• EPA Substance Registry System: EPA(73167-03-0)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 3
• WGK Germany: 3
• F: 8-10-23
• Hazardous Substances Data: 73167-03-0(Hazardous Substances Data)

Usage

Description

Icosapent sodium, also known as cis-5,8,11,14,17-Eicosapentaenoic acid sodium salt, is a pharmaceutical compound derived from fish oil. It is a type of omega-3 fatty acid that has various health benefits and is used for the treatment and prevention of cardiovascular diseases.
Used in Pharmaceutical Industry:
Icosapent sodium is used as a pharmaceutical agent for reducing thromboxane A2 production and platelet aggregation. It helps in preventing arteriosclerosis and improving cardiovascular health.
Used in Research and Development:
Icosapent sodium is used as a research compound for studying its effect on the pathology of lupus in drug-induced and spontaneous mouse models. It helps in understanding the underlying mechanisms of lupus and developing potential therapeutic interventions.
Used in Pre-treatment of Mouse Alveolar Macrophages:
Icosapent sodium is used as a pre-treatment agent for mouse alveolar macrophages to study the effect and relationship between amiodarone and eicosapentaenoic acid (EPA) concerning cytokine release. This helps in understanding the interaction between these two compounds and their impact on immune responses.
Used in Pharmacological Correction with EPA Supplementation:
Icosapent sodium is used for pharmacological correction with EPA supplementation to examine if it might restore autophagic flux and reduce renal lipotoxicity in mice. This helps in understanding the potential therapeutic effects of Icosapent sodium in treating kidney diseases and improving overall health.

Biochem/physiol Actions

Eicosapentaenoic acid (EPA) possesses anti-hyperglycemic, anti-oxidant, anti-hyperlipidemic, and anti-inflammatory properties. It aids in improving vasoreactivity. EPA is capable of suppressing vascular smooth muscle proliferation. It ameliorates pulmonary hypertension by preventing Fyn kinase activity. EPA exhibits a beneficial effect on lipid metabolism. It is used to treat hypercholesterolemia and atherosclerosis.

InChI:InChI=1/C20H30O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22);/b4-3-,7-6-,10-9-,13-12-,16-15-;